Zhejiang Wenda Pharmaceutical Technology has received Breakthrough Therapy Designation from China’s National Medical Products Administration for NHWD-870 HCI, its novel oral BET inhibitor being developed for advanced thoracic midline NUT carcinoma in patients who have failed prior chemotherapy.

The designation is significant because NUT carcinoma remains a rare and highly aggressive cancer with few effective treatment options. The disease is characterised by NUTM1 gene rearrangement and is often diagnosed at an advanced stage due to non-specific clinical symptoms and limited awareness.

According to the company, NUT carcinoma has a median survival of approximately 6.5 months and commonly occurs in the lungs, head and neck regions. The median age of onset is reported to be 23.6 years, underscoring the clinical impact of the disease on younger patients.